TH9507: an experimental treatment for lipodystrophy.

Anne Monroe

Research output: Contribution to journalArticle

Abstract

As the use of highly active antiretroviral therapy (HAART) became widespread, HIV positive individuals and their physicians began to notice changes in body fat distribution, with excess fat or fat loss noted in different areas. These body shape changes are sometimes accompanied by metabolic abnormalities, such as insulin resistance and elevated blood fats. Collectively, these changes are known as lipodystrophy syndrome. Treatment options for lipodystrophy are somewhat limited. Growth hormone has been used with success in clinical trials to reduce visceral adipose tissue, fat that collects around the abdominal organs. A new product, TH9507, a synthetic growth hormone releasing hormone analog made by the Canadian pharmaceutical company Theratechnologies, is currently showing promise in clinical trials and may represent a new treatment option for people with some types of lipodystrophy.

Original languageEnglish (US)
Pages (from-to)16-19
Number of pages4
JournalBETA bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS foundation
Volume19
Issue number4
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Lipodystrophy
Fats
Clinical Trials
Body Fat Distribution
Growth Hormone-Releasing Hormone
Intra-Abdominal Fat
Highly Active Antiretroviral Therapy
Therapeutics
Growth Hormone
Insulin Resistance
HIV
Physicians
tesamorelin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

TH9507 : an experimental treatment for lipodystrophy. / Monroe, Anne.

In: BETA bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS foundation, Vol. 19, No. 4, 06.2007, p. 16-19.

Research output: Contribution to journalArticle

@article{341fd8801de54d2099185c58cc144cef,
title = "TH9507: an experimental treatment for lipodystrophy.",
abstract = "As the use of highly active antiretroviral therapy (HAART) became widespread, HIV positive individuals and their physicians began to notice changes in body fat distribution, with excess fat or fat loss noted in different areas. These body shape changes are sometimes accompanied by metabolic abnormalities, such as insulin resistance and elevated blood fats. Collectively, these changes are known as lipodystrophy syndrome. Treatment options for lipodystrophy are somewhat limited. Growth hormone has been used with success in clinical trials to reduce visceral adipose tissue, fat that collects around the abdominal organs. A new product, TH9507, a synthetic growth hormone releasing hormone analog made by the Canadian pharmaceutical company Theratechnologies, is currently showing promise in clinical trials and may represent a new treatment option for people with some types of lipodystrophy.",
author = "Anne Monroe",
year = "2007",
month = "6",
language = "English (US)",
volume = "19",
pages = "16--19",
journal = "BETA bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS foundation",
issn = "1058-708X",
publisher = "San Francisco AIDS Foundation",
number = "4",

}

TY - JOUR

T1 - TH9507

T2 - an experimental treatment for lipodystrophy.

AU - Monroe, Anne

PY - 2007/6

Y1 - 2007/6

N2 - As the use of highly active antiretroviral therapy (HAART) became widespread, HIV positive individuals and their physicians began to notice changes in body fat distribution, with excess fat or fat loss noted in different areas. These body shape changes are sometimes accompanied by metabolic abnormalities, such as insulin resistance and elevated blood fats. Collectively, these changes are known as lipodystrophy syndrome. Treatment options for lipodystrophy are somewhat limited. Growth hormone has been used with success in clinical trials to reduce visceral adipose tissue, fat that collects around the abdominal organs. A new product, TH9507, a synthetic growth hormone releasing hormone analog made by the Canadian pharmaceutical company Theratechnologies, is currently showing promise in clinical trials and may represent a new treatment option for people with some types of lipodystrophy.

AB - As the use of highly active antiretroviral therapy (HAART) became widespread, HIV positive individuals and their physicians began to notice changes in body fat distribution, with excess fat or fat loss noted in different areas. These body shape changes are sometimes accompanied by metabolic abnormalities, such as insulin resistance and elevated blood fats. Collectively, these changes are known as lipodystrophy syndrome. Treatment options for lipodystrophy are somewhat limited. Growth hormone has been used with success in clinical trials to reduce visceral adipose tissue, fat that collects around the abdominal organs. A new product, TH9507, a synthetic growth hormone releasing hormone analog made by the Canadian pharmaceutical company Theratechnologies, is currently showing promise in clinical trials and may represent a new treatment option for people with some types of lipodystrophy.

UR - http://www.scopus.com/inward/record.url?scp=38449100116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449100116&partnerID=8YFLogxK

M3 - Article

C2 - 18069152

AN - SCOPUS:38449100116

VL - 19

SP - 16

EP - 19

JO - BETA bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS foundation

JF - BETA bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS foundation

SN - 1058-708X

IS - 4

ER -